Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
“2020 has been a transformational year for Valneva”CEO Thomas Lingelbach comments on Valneva's 2020 achievements and focus for 2021
Investor Access Event, Paris
Investor Relations TeamCampus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 firstname.lastname@example.org
Subscribe to Valneva News